Tenaya Therapeutics appoints Eric Hyllengren as CFO effective July 13, 2026

Tenaya Therapeutics, Inc.

Eric Hyllengren joins as CFO; previously CFO at Zura Bio, CFO/COO at Atara Biotherapeutics.
Hyllengren receives $490k base salary, 40% target bonus, option to purchase 1.65M shares.
SVP Finance Tomohiro Higa to retire in Q3 2026; will remain as consultant for transition.
CEO Faraz Ali and Tomohiro Higa cease as interim PFO and acting PAO as of July 13.
Hyllengren brings 20+ years experience in biotech finance, capital markets, corporate strategy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.